SCI Pharmtech Inc
TWSE:4119
SCI Pharmtech Inc
Net Income (Common)
SCI Pharmtech Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Net Income (Common)
NT$484.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
7%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Net Income (Common)
NT$1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
![]() |
Formosa Laboratories Inc
TWSE:4746
|
Net Income (Common)
NT$392.9m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
16%
|
CAGR 10-Years
5%
|
|
![]() |
ScinoPharm Taiwan Ltd
TWSE:1789
|
Net Income (Common)
NT$399.4m
|
CAGR 3-Years
26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-6%
|
|
![]() |
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Net Income (Common)
NT$4.3B
|
CAGR 3-Years
43%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
![]() |
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Net Income (Common)
NT$847.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
SCI Pharmtech Inc
Glance View
SCI Pharmtech Corp. is engaged in the biotechnology and medical care industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2002-08-12. The firm's main products include APIs, API intermediates and special and precision chemicals. The firm distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
See Also
What is SCI Pharmtech Inc's Net Income (Common)?
Net Income (Common)
484.2m
TWD
Based on the financial report for Sep 30, 2024, SCI Pharmtech Inc's Net Income (Common) amounts to 484.2m TWD.
What is SCI Pharmtech Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
7%
Over the last year, the Net Income (Common) growth was 28%.